跳至主要内容
临床试验/NCT04509414
NCT04509414已完成4 期

Intranasal Dexmedetomidine Versus Midazolam for Premedication in Deep-sedated Pediatric Dental Patients: a Double-blinded, Prospective, Randomized Controlled Trial

Peking University1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2020年4月10日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
100
试验地点
1
主要终点
venipuncture acceptance

研究概览

简要总结

It is important to choose an appropriate analgesia/sedation technique in pediatric dental treatment. Premedication combined with intravenous anesthesia is often used in deep sedation technique for pediatric dental treatment and it's a routine in most hospitals. Deep sedation has its unique advantages such as avoiding the airway damage with an enhanced recovery.

Dexmedetomidine is suitable for intranasal mucosal administration as a premedication drug. It has been proved with several beneficial characteristics in other clinical procedures.

This study intends to further explore the characteristics of nasal dexmedetomidine as premedication in pediatric oral treatment under deep sedation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
3 Years 至 7 Years(Child)
性别
All
接受健康志愿者

入选标准

  • children in need of deep sedation for dental treatment aged 3-7 years.
  • anticipated operation time 1-2hours

排除标准

  • any known medical records with neural or mental disorder
  • any known medical records with severe systemic disorder
  • history of sedation drug administration in recent 1 months
  • any known allergic history of dexmedetomidine, midazolam or propofol
  • morbid obesity
  • history of OSAHS or acute respiratory infection in 2 weeks
  • other conditions which the attending considers to be unfit for the trial

研究组 & 干预措施

dexmedetomidine

Experimental

2ug/kg intranasal atomized dexmedetomidine

干预措施: Dexmedetomidine (Drug)

midazolam

Active Comparator

0.2mg/kg intranasal atomized midazolam

干预措施: Midazolam (Drug)

结局指标

主要结局

venipuncture acceptance

时间窗: Day 0

acceptance while starting the IV line, at most 2 tries

次要结局

  • hypoxemia(Day 0)
  • post-operative agitation(Day 0)
  • discharge time(Day 0)
  • times of intra-operative airway assistance(Day 0)
  • post-operative pain(Day 0)
  • remedial mask induction acceptance(Day 0)
  • propofol dosage(Day 0)
  • peri-operative blood pressure(Day 0)
  • peri-operative heart rate(Day 0)
  • Observer's Assessment of Alertness/Sedation(MOAA/S) Score(Day 0)
  • patients' discomfort(up to 24 hours)

研究者

发起方
Peking University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Yang Xudong

Chief of Department of Anesthesiology

Peking University

研究点 (1)

Loading locations...

相似试验